and individuals with active tuberculosis or hepatitis-Bassociated severe chronic liver disease. The decision to increase the threshold CD4 count from the 350 cells per μL recommended in 2010 was reached through a structured GRADE (Grading of Recommendations Assessment, Development and Evaluation) review process that assessed evidence for the clinical and epidemiological benefi ts of earlier HIV initiation. 2 Evidence that antiretroviral therapy reduces HIV infectiousness 3, 4 suggests that increasing the number of HIV-positive adults who are on treatment could have the potential to change the course of the epidemic in highly aff ected regions. 5, 6 However, the resources necessary to implement these changes could be substantial. 1 The recommendation for earlier initiation of antiretroviral therapy comes at a time when progress towards implementation of antiretroviral therapy is varied: at the end of 2012 only an estimated 61% of HIV-positive individuals with CD4 counts of 350 cells per μL or less in low-income and middle-income countries were receiving treatment. 7 Even in settings where high coverage has been achieved, many patients start treatment late because of late HIV diagnosis and poor linkage to and retention in pre-antiretroviral care. [8] [9] [10] In this context, decision makers have to consider whether resources should be devoted to implementing earlier eligibility, achieving high coverage and timely initiation of antiretroviral therapy for individuals with the greatest clinical need, or expanding other health programmes that might generate greater health gains. This decision should be based on assessment of the populationlevel benefi ts and costs of strategies to expand eligibility for antiretroviral therapy or increase coverage, accounting for the additional resources that would be needed. Whereas clinical trials can be used to assess the eff ect of expanded eligibility criteria for individuals, mathematical models can be used to project the long-term eff ects of policy decisions. 11 In the past decade, mathematical models have been useful for understanding the potential epidemiological eff ects, public health benefi ts, and costs of antiretroviral therapy in many populations. 5, [11] [12] [13] [14] To better inform policy for antiretroviral therapy, we assembled 12 independently developed HIV epidemic models to generate estimates for the health benefi ts, costs, and cost-eff ectiveness of earlier eligibility for antiretroviral therapy using the most recent available evidence. We also assessed the cost-eff ectiveness of increasing HIV testing and linkage to care to improve coverage of antiretroviral therapy. The use of several models allows for the identifi cation of conclusions that can be robustly reproduced across models, which is crucial in view of the wide range of results seen in previous analyses. 6 Because optimum strategies might be expected to diff er in settings with diff erent epidemic types, existing coverage of antiretroviral therapy, and income, we selected four countries with existing models of the eff ect of antiretroviral therapy as case studies in an eff ort to produce guidance applicable to a broad set of epidemic settings: South Africa (generalised epidemic, moderate antiretroviral therapy coverage), Zambia (generalised epidemic, high antiretroviral therapy coverage), India (concentrated epidemic, moderate antiretroviral therapy coverage), and Vietnam (concentrated epidemic, low antiretroviral therapy coverage).
Methods Overview
We assessed the potential eff ect of changes to adult eligibility guidelines for antiretroviral therapy and improvements in HIV testing and linkage to care in four low-income and middle-income countries. We calibrated existing, independently developed mathematical models to epidemic settings in South Africa (seven models), Zambia (four models), India (three models), and Vietnam (one model). All models were dynamic HIV transmission models that simulate HIV transmission in populations and HIV disease progression, and incorporate both the therapeutic benefi ts of antiretroviral therapy for reducing HIV morbidity and mortality and the preventive benefi ts associated with reduced HIV infectiousness (table 1) .
We used model outputs that describe changes in the use of health care to estimate changes in costs borne by the HIV programme and the broader health system. We estimated the eff ects of intervention strategies on HIV incidence, antiretroviral therapy costs and nonantiretroviral therapy health-care costs, and disabilityadjusted life-years (DALYs) averted by comparing model projections of diff erent antiretroviral therapy eligibility and access strategies over 20 years. We calculated incremental cost-eff ectiveness ratios (ICERs; reported as cost per DALY averted) to compare alternative strategies.
Epidemiological modelling
The models represented three eligibility criteria by which antiretroviral therapy could be started for adult patients in care: HIV-positive adults with a CD4 count of 350 cells per μL or less (assumed to be the existing, baseline strategy); HIV-positive adults with a CD4 count of 500 cells per μL or less; and all HIV-positive adults. Each model simulated a baseline projection representing existing treatment coverage (ie, patterns of HIV testing, linkage to and retention in pre-antiretroviral care, and uptake of antiretroviral therapy), which we refer to as the status-quo access to HIV care.
All three eligibility criteria were simulated with the assumption of a continuation of status-quo access to HIV care-ie, patients started on antiretroviral therapy are those already being linked to HIV care programmes in accordance with existing patterns of access. Models also simulated each eligibility strategy with the assumption of substantial increases in routine HIV testing and linkage to care across the adult population, such that 80% of adults infected with HIV would be in care when they became eligible for antiretroviral therapy. For concentratedepi demic settings (India and Vietnam), models examined increased HIV testing and linkage to care in specifi c key populations (female sex workers, men who have sex with men, and injecting drug users), such that 80% of these populations had access to antiretroviral therapy, while access for the general population remained at the status quo.
Alternative strategies for antiretroviral therapy eligibility and coverage of HIV care were simulated for a 20 year period from the beginning of 2014 to the end of 2033. For strategies involving expanded access to HIV care, the simulated change in access was implemented gradually over 2 years from the beginning of 2014.
Estimation of costs and cost-eff ectiveness
We assessed incremental costs of each strategy from a health-system perspective, using a common costing framework across all models. The costs included were: service delivery costs necessary to identify and link HIVpositive individuals to care; service delivery costs for patients receiving antiretroviral therapy or pre-antiretroviral care; potential cost savings due to reduced use of health care in the wider health system as HIV-positive individuals start to receive care through the HIV programme; and costs associated with programmatic support and supply-chain management (table 2). All costs are in addition to the basic amount of spending needed to support the programme. Country-specifi c unit cost accounted for diff erences in prices between countries, and all costs are reported in 2012 US$. The upfront costs of infrastructure investments are spread over their useful lifetime. The costing framework and sources of cost estimates are described in the appendix (pp 9-14).
We summarised health benefi ts as DALYs averted, which capture improvements in both survival and quality of life that result from the direct benefi ts of antiretroviral therapy in extending life for HIV-positive individuals and from reduced numbers of HIV infections. Disability weights (table 3) were drawn from the Global Burden of Disease Study 2010, 28 which assessed the value of life-years lived in diff erent health states compared with full health.
We calculated ICERs as the incremental cost per DALY averted over 20 years by an intervention compared with a less eff ective, less costly alternative. Costs and health benefi ts were discounted by 3% per year. 29 On the basis of WHO recommended benchmarks, an intervention was classifi ed as very cost eff ective if its ICER was less than the country's per-head gross domestic product (GDP) in 2012 (South Africa $8040; Zambia $1425; India $1489; Vietnam $1407), 30 and cost eff ective if it was less than three times the per-head GDP. . ‡Concentrated epidemic models (India and Vietnam) assess expanded testing and linkage to care among these populations. §All models simulate eligibility for antiretroviral therapy for adult patients with CD4 counts of 350 cells per μL or less, and eligibility for all HIV-positive adults. ¶The Mishra model was also used for a second baseline simulation in which the increases in condom usage and access to antiretroviral therapy for female sex workers that followed the implementation of the Avahan intervention programme 25 had not occurred and access to antiretroviral therapy for HIV-positive individuals (including female sex workers) remained poor, resulting in higher HIV incidence. 
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Role of the funding source
Authors from WHO contributed to the design of the study, and the selection of settings investigated and strategies assessed, but had no role in the development or selection of epidemiological models, conduct of the analyses, or interpretation of results. The Bill & Melinda Gates Foundation had no role in the design of the analysis, interpretation of the results, or the decision to submit for publication. The corresponding author had fi nal responsibility for the decision to submit for publication.
Results
We fi rst examined whether it would be cost eff ective to change antiretroviral therapy eligibility criteria for adults in generalised-epidemic settings (ie, South Africa and Zambia). In South Africa, the ICER for changing the CD4 count threshold from 350 cells per μL to 500 cells per μL ranged from $273 to $1691 per DALY averted over 20 years (results from six models; fi gure 1). The cost per DALY averted for changing eligibility to all HIVpositive adults compared with eligibility for those with CD4 counts of 350 cells per μL or less ranged from $438 to $3790 (seven models). In Zambia, the ICER for expanding eligibility to patients with CD4 counts of 500 cells per μL or less ranged from improving health outcomes while reducing costs (ie, dominating the previous guidelines) to $749 per DALY averted (four models). For expanding eligibility to all HIV-positive adults compared with eligibility for those with CD4 counts of 350 cells per μL or less, results ranged from dominating the previous guidelines to $790 per DALY (four models). The lower cost-eff ectiveness ratios in Zambia compared with South Africa are partly due to lower nonantiretroviral costs in Zambia (table 2) . For South Africa and Zambia, most models showed slightly higher costs per DALY averted for expanding antiretroviral therapy eligibility to all HIV-positive adults compared with expansion to those with CD4 counts of 500 cells per μL or less (fi ve of six models for South Africa and two of four for Zambia). However, these models also showed that the expansion of eligibility from a CD4 threshold of 500 cells per μL to all HIV-positive adults was still either cost eff ective or very cost eff ective (fi gure 1). 
Supply-chain management and programmatic support (% mark-up)
Supply-chain management* 20% 20% 20% 20%
Programmatic support † 50% 50% 50% 50%
All costs are in 2012 US$. ART=antiretroviral therapy. *Mark-up assessed on the basis of antiretroviral drug costs. †Mark-up assessed on the basis of all costs apart from antiretroviral drugs. Repeating the analysis for generalised epidemics with an assumption of greatly expanded HIV testing and linkage to care generated similar cost-eff ectiveness ratios (appendix pp [20] [21] . ICERs that compared costs and benefi ts over a shorter time period were much greater than for the full 20 year period (appendix pp 20-21): for example, in South Africa, over 5 years the highest ICER for changing the CD4 count threshold from 350 cells per μL to 500 cells per μL was $11 646, compared with $1691 over a 20 year period (with the assumption of status-quo treatment coverage). This fi nding is because the eff ect of increased use of antiretroviral therapy in reducing HIV transmission tends to increase over time in the models (appendix p 18).
We next examined the cost-eff ectiveness of changing the eligibility criteria in concentrated-epidemic settings. In Vietnam, where the HIV epidemic is driven by female sex workers, men who have sex with men, and injecting drug users, the ICER was $290 for changing the CD4 count threshold from 350 cells per μL to 500 cells per μL and $289 for extending eligibility to all HIV-positive adults. In Bangalore, India, where the epidemic is driven by female sex workers and men who have sex with men, the ICER associated with eligibility for all HIV-positive adults compared with eligibility for those with CD4 counts of 350 cells per μL or less was $131 per DALY averted. In Manipur, India, where HIV is mainly spread by unsafe drug injection, the ICER for extending eligibility to all HIV-positive adults was $197 compared with eligibility for those with CD4 counts of 350 cells per μL or less. All of these policy changes would be very cost eff ective.
In Belgaum district in southern India, where the epidemic is mainly associated with female sex workers, the ICER for eligibility for all HIV-positive adults compared with eligibility for those with CD4 counts of 350 cells per μL or less was $198 per DALY averted. Belgaum has undergone substantial reductions in HIV incidence in the past decade, associated with targeted interventions that have increased condom use and access to HIV care and treatment among sex workers. 25, 31 In a simulated scenario in which this intervention programme did not exist, the ICER would be $241 per DALY averted. Thus, earlier eligibility for antiretroviral therapy would be very cost eff ective in epidemic settings similar to Belgaum with or without such programmes.
Change in eligibility for initiation of antiretroviral therapy is only one way in which decision makers could respond to the new guidelines. They could instead invest in expanding access (ie, HIV testing and linkage to care) to improve treatment coverage for individuals in greatest need (with CD4 counts of 350 cells per μL or less), or they could simultaneously adopt earlier eligibility criteria and expand testing and linkage to care. We also used the model results to compare these alternatives.
The relative eff ects of these competing approaches with respect to incidence reduction diff ered between settings (fi gure 2). In South Africa, where existing antiretroviral therapy coverage is moderate, expansion of eligibility to adults with CD4 counts of 500 cells per μL or less would avert only 5-12% of new infections over 20 years. By contrast, expansion of testing and linkage to care while maintaining the CD4 count threshold of 350 cells per μL would have a larger eff ect across the models (6-28% of infections averted). Changing eligibility to all HIV-positive adults would avert 9-32% without expansions in testing and linkage, Cost per DALY averted (US$ thousands)
South Africa
Goals STDSIM EMOD BBH PopART Synthesis Menzies CD4 ≤500 cells per μL vs CD4 ≤350 cells per μL All HIVpositive vs CD4 ≤350 cells per μL All HIVpositive vs CD4 ≤500 cells per μL -1 0 1 2 3 4 Zambia Goals EMOD Macha PopART All HIV-positive vs CD4 ≤350 cells per μL 0 1 2 3 4 India Belgaum Belgaum (without condom intervention) Bangalore IDU-Manipur CD4 ≤500 cells per μL vs ≤350 cells per μL All HIVpositive vs ≤350 cells per μL All HIVpositive vs ≤500 cells per μL 0 1 2 3 4
Vietnam
Prevtool or 19-60% with such expansions. This relation is reversed in Zambia, which has higher coverage of antiretroviral therapy than South Africa: in all models, expansion of eligibility to all HIV-positive adults (21-40% infections averted) averted more infections than expansion of testing and linkage to care while maintaining the CD4 count threshold of 350 cells per μL (8-17%).
In both South Africa and Zambia, the additional costs of strategies that expand testing and linkage to care are much higher than the costs of strategies that only change eligibility (fi gure 3). Earlier initiation of antiretroviral therapy for people who are already attending the clinic has a fairly low incremental cost because the cost of the additional years of antiretroviral In the generalised-epidemic settings (South Africa and Zambia), expanded access refers to expanded testing and linkage to care for the general population. In concentrated-epidemic settings (India and Vietnam), expanded access refers to expanded testing and linkage to care for all high-risk groups (female sex workers, men who have sex with men, and injecting drug users). therapy are partly off set by savings in pre-antiretroviral monitoring and other averted health-care costs. By contrast, strategies that expand testing and linkage to care require additional expenditure for HIV testing, preantiretroviral monitoring, and antiretroviral therapy for patients diagnosed through expanded testing. If the objective is to maximise the health returns per dollar spent, as an initial step of programme expansion, countries could prioritise the strategy that has the lowest cost per DALY averted (fi gure 4). All models for Zambia suggest that expanding eligibility has the lowest cost per DALY averted. This result is robust to alternative assumptions about the relative costs of HIV testing and linkage, pre-antiretroviral monitoring, and provision of antiretroviral therapy (fi gure 4). Four of seven models for South Africa suggest the same, but three models instead suggest that expanding testing and linkage to care would have the lowest cost per DALY averted. Overall, these results suggest that in settings with moderate to high coverage, expanding eligibility might be the preferred initial strategy. But expanding testing and linkage to care while maintaining the CD4 count eligibility threshold of 350 cells per μL might be a preferred initial strategy in settings with lower coverage, especially if testing and preantiretroviral monitoring costs are low compared with the costs of providing antiretroviral therapy. Ultimately, both forms of expansion (ie, eligibility and testing and linkage) would be cost eff ective relative to benchmarksif a country were to proceed by initially expanding in one way, it would still be cost eff ective to extend services in the other way subsequently.
Whereas in generalised epidemics testing and linkage campaigns were assumed to be implemented in the general population, in concentrated epidemics it might be preferable to focus resources on specifi c populations. In Belgaum, India, expanding eligibility to all HIVpositive female sex workers, to all HIV-positive adults, or to all HIV-positive adults (with expanded HIV testing and linkage to care for female sex workers) would all be very cost eff ective. The more extensive of these strategies would lead to greater reductions in new infections, albeit at a greater cost per DALY averted (table 4) . However, intervention to expand testing and linkage to care for all adults in the general population resulted in an ICER of $5648 per DALY, which would not be cost eff ective, although it could lead to the largest eff ect on HIV incidence (53% of infections averted). Each of these interventions had lower ICERs in the simulated scenario that did not include the eff ect of the prevention programmes in Belgaum (table 4) .
For Vietnam, results were qualitatively similar to Belgaum (table 4); whereas expanding eligibility for the whole population and intervening to expand testing and linkage to care for female sex workers, men who have sex with men, and injecting drug users would be cost eff ective, interventions to expand testing and linkage for the whole population would not (ICER $21 549).
Discussion
In all settings and across all models, extension of adult eligibility for antiretroviral therapy to people already in care with CD4 counts of 500 cells per μL or less, or to all HIV-positive adults was very cost eff ective over a 20 year period. These fi ndings refl ect the fairly low cost of providing additional years of antiretroviral therapy to people in care and the assumption that expanded access to antiretroviral therapy will reduce HIV transmission in the whole population, adding to the well established clinical benefi ts of antiretroviral therapy in the reduction of morbidity and improvement of survival of HIVpositive individuals (panel).
In the generalised-epidemic settings we examined, all models suggested that immediate implementation of the new WHO clinical recommendations for patients with CD4 counts of 500 cells per μL or less to start treatment would be cost eff ective, even in settings where testing and linkage to care are still being increased to achieve universal access under the 2010 guidelines (in which patients are eligible if their CD4 cell count is 350 cells per μL or less). However, the models also show that, in settings where treatment coverage is incomplete, changing the eligibility criteria alone without an increase in access to HIV care, although cost eff ective, would have a smaller eff ect on health than would be achieved by increasing coverage of antiretroviral therapy for patients with a CD4 cell count of 350 cells per μL or less. Our modelling did not take into account cases in which resources are severely constrained, resulting in waiting lists of patients with low CD4 cell counts, or situations in which earlier eligibility would reduce access to antiretroviral therapy for patients with the greatest therapeutic need. The WHO guidelines 1 recommend that, in such cases, treatment should be prioritised for patients with CD4 counts of 350 cells per μL or less.
In concentrated-epidemic settings, we estimated that extending eligibility for antiretroviral therapy to all HIVpositive adults or those with CD4 counts of 500 cells per μL or less already in care would be very cost eff ective. We also estimated that increases in HIV testing to achieve universal access to immediate antiretroviral therapy for members of specifi c populations-namely Change eligibility to CD4 count ≤500 cells per μL Change eligibility to all HIV-positive adults Expand access, eligibility criteria unchanged Change eligibility to CD4 count ≤500 cells per μL and expand access Change eligibility to all HIVpositive adults and expand access female sex workers, men who have sex with men, and injecting drug users would be very cost eff ective in India, and cost eff ective in Vietnam. By contrast, widespread interventions to uniformly expand access to testing and treatment services for the general population were not estimated to be cost eff ective in concentrated-epidemic settings. Other testing strategies not included in our analyses, such as provider-initiated testing, might be more effi cient at identifying HIV-positive adults, and could potentially be cost eff ective in these settings. Our results also suggest that investments in earlier eligibility for antiretroviral therapy should be regarded as a long-term investment in population health. Although upfront costs are high, the health benefi ts generated by expanded eligibility increase over time (appendix p 18), such that the cost of averting ill health and premature death becomes progressively lower as cost and benefi ts are assessed over longer time periods (appendix pp [20] [21] [22] [23] . However, by contrast with the conclusions of earlier analyses, 5, 12, 32 our results did not show that the most eff ective interventions will be cost-saving over a 20 year period.
This analysis brought together several independent models to examine the same policy question, and their collective fi ndings were in general agreement about the cost-eff ectiveness of earlier eligibility for antiretroviral therapy. The variation in some of the model results emphasises existing uncertainties and key directions for further data collection. Factors that contribute to this variation include diff erent fundamental representations of the underlying epidemiology of HIV transmission and diff erent expectations about future patterns of treatment uptake and eff ectiveness. Several studies currently in progress or planned will provide further data about other key assumptions that directly underlie our conclusionsparticularly with respect to the therapeutic benefi ts of earlier antiretroviral therapy (NCT00867048, NCT00495651), the scaling up of the individual prevention effi cacy of antiretroviral therapy to produce populationlevel health benefi ts 33 and the eff ect of antiretroviral therapy on risk behaviours (NCT01965470, NCT01900977, and NCT01509508), and the reduction of transmission risk through use of antiretroviral therapy by men who have sex with men 34 and injecting drug users. 35 Comparisons of model predictions with observational data can be useful. The epidemiological eff ects of high antiretroviral therapy coverage in high-income countries have seemingly been mixed, 36 All costs are in 2012 US$. Proportion of infections averted, cumulative disability-adjusted life-years (DALYs) averted, and cumulative additional costs over 20 years are relative to eligibility for patients with CD4 counts of 350 cells per μL or less and status-quo access to HIV care (undiscounted).*Incremental cost-eff ectiveness (ICER) is the incremental cost per DALY averted over 20 years relative to the next most expensive strategy (excluding dominated strategies, which produce fewer health benefi ts at higher cost); costs and estimated DALYs averted discounted at 3% per year. †Dominated strategy. 39 in rural South Africa showed that the risk of HIV infection was lower for individuals living in areas with higher coverage of antiretroviral therapy, 42 and studies have not shown increases in sexual risk behaviour by people given early antiretroviral therapy 43, 44 or the general population. 45 As in all scientifi c endeavours, the conclusions of this analysis should be reassessed as new data become available.
The paucity of data for the costs of managing and supporting front-line services, the costs of scaling up and maintaining expanded testing programmes, and the fl ow of patients through care services also add uncertainty to our estimates. Growing evidence suggests that unit costs will decrease as service provision sites expand and mature. [46] [47] [48] However, how this eff ect will translate to scale-up within a national programme context, which would probably involve expansion of existing sites as well as creation of new treatment sites and possibly novel care platforms, is unclear. Therefore, the experiences in countries that rapidly adopt earlier treatment and achieve high coverage should be used to provide better information about the epidemiological and economic eff ects that might be encountered by other countries.
We assessed cost-eff ectiveness using a convention that approximates the social willingness to pay to achieve health gains with a country's per-head GDP. Interventions shown to be cost eff ective on the basis of this benchmark can be taken to be a reasonable investment, relative to a country's present level of income. 29 However, this suggestion does not mean that the present amount or distribution of health spending is optimum, or that other interventions (for HIV or other health issues) might not produce greater health gains per dollar spent. For example, analyses of medical male circumcision suggest that expansion of access to circumcision might have a lower ICER than expansion of access to antiretroviral therapy, 18 and might even be cost-saving in the long term. 49 National policy making will require explicit comparisons of alternative spending portfolios, which might include other interventions and a broader array of antiretroviral therapy and HIV-testing strategies. Similarly, countries will need to weigh aff ordability and feasibility when considering large expansions in access to or eligibility for antiretroviral therapy. Implementing these strategies could require large, one-time investments in the years immediately after a policy change. In view of these costs and the uncertainties involved, some countriesespecially those with low coverage of antiretroviral therapy at present-could decide to take a gradual approach to changing the eligibility criteria.
For this study we adopted an analytical approach that assesses total health attainment (total DALYs averted) and is indiff erent to how these health benefi ts are distributed. For this reason, our results do not take into account other considerations for decisions makers, such as equity of treatment access. The conclusions of this analysis could therefore diff er from those of a narrower analysis focused only on the health benefi ts for people receiving antiretroviral therapy, especially since studies are still in progress to quantify the direct health benefi ts of antiretroviral therapy at high CD4 cell counts. 50 For the economic analysis we adopted a health-systems perspective, which excludes some economic outcomes that might be valued by decision makers, such as reduced orphanhood, improved productivity, and survival of working-age adults. For all of these reasons, the general guidance from the four country case studies undertaken in this analysis should be regarded as an input into a decision-making process that weighs all locally relevant considerations, rather than a policy prescription.
The revised WHO recommendations 1 have required decision makers to reconsider policies around anti -retroviral therapy eligibility and treatment coverage, even while trials and demonstration projects are underway to quantify the consequences of expanded HIV treatment. As a result, uncertainties persist about key outcomes of these policies. 51 However, informed by currently available epidemiological, biological, and economic information, the consensus fi nding of this study is that extending eligibility for antiretroviral therapy to all adults with CD4 counts of 500 cells per μL or less, and potentially to all HIV-positive adults, would be cost eff ective and
Panel: Research in context
Systematic review
Recently WHO issued revised guidance for the use of antiretroviral therapy that includes the recommendation that HIV-positive adults should start receiving antiretroviral therapy when their CD4 count falls to 500 cells per μL or less. 1 Countries now have to decide whether to adopt and implement these recommendations. Reductions in HIV infectiousness for people who start antiretroviral therapy earlier 3 mean that both the individual therapeutic benefi ts and prevention benefi ts have to be taken into account when assessing the public health benefi ts of earlier eligibility for antiretroviral therapy. Many mathematical models have been developed to examine the population-level health benefi ts and costs of diff erent strategies for antiretroviral therapy in low-income and middle-income country settings, and previous work has shown that results from diff erent analyses can vary widely. 6 This fi nding suggests that taking into account results across diff erent models and epidemic settings is essential for assessing the health eff ect and cost-eff ectiveness of earlier eligibility to inform policy decisions.
Interpretation
Expanding eligibility for antiretroviral therapy to adult patients with CD4 counts of 500 cells per μL or less, or to all HIV-positive adults was cost eff ective over 20 years in low-income and middle-income countries, relative to conventional WHO cost-eff ectiveness benchmarks. Adoption of these recommendations should be considered alongside other high-priority health interventions in low-income and middleincome countries. In generalised-epidemic settings, broad expansions of HIV testing and linkage to care to improve programme access was cost eff ective and should also be considered by policy makers. In concentrated-epidemic settings, increased HIV testing and linkage to care for key populations at risk of transmitting HIV was very cost eff ective and should be considered where possible. Widespread HIV testing programmes aimed at the entire adult population did not seem to be cost eff ective in concentrated-epidemic settings, suggesting that health resources might be better allocated elsewhere.
